Get the Stockscreener App
0.564
2.99%
-0.0179
Kala Bio Inc stock is traded at $0.564, with a volume of 295.77K.
It is down -2.99% in the last 24 hours and down -13.15% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.5819
Open:
$0.5642
24h Volume:
295.77K
Relative Volume:
0.04
Market Cap:
$15.71M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.0452
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
-6.32%
1M Performance:
-13.15%
6M Performance:
-93.02%
1Y Performance:
-93.25%
1-Day Range:
$0.563
$0.59
1-Week Range:
$0.563
$0.6293
52-Week Range:
$0.51
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.564 | 16.21M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.21 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.57 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
867.25 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.42 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.70 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO Receives Nasdaq Notice on Listing Compliance - TipRanks
KALA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
KALA Stock Price, Forecast & Analysis | KALA BIO INC (NASDAQ:KALA) - Chartmill
Aug EndMonth: Is Codere Online Luxembourg SAs ROIC above industry averagePortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trading Action: Can LOAN weather a recessionTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
Can KALA BIO Inc stock outperform in a bear marketWeekly Profit Analysis & Breakout Confirmation Trade Signals - baoquankhu1.vn
Why KALA BIO Inc stock is a must watch in 2025July 2025 PostEarnings & Community Driven Trade Alerts - Bộ Nội Vụ
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
KALA BIO Launches At-the-Market Equity Offering Program - TipRanks
Why hedge funds are buying KALA BIO Inc. stockPortfolio Growth Summary & Risk Adjusted Swing Trade Ideas - Улправда
Can KALA BIO Inc. stock weather global recessionJuly 2025 Final Week & Real-Time Chart Breakout Alerts - Улправда
KALA BIO eliminates debt overhang through equity settlements - TipRanks
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
KALA BIO Clears Oxford DebtA Fresh Start Ahead? - Nasdaq
KALA BIO Settles Approximately $10.6 million of Debt - The Manila Times
Kala Bio Settles $10.6 Million Debt; Shares Rise After-Hours - MarketScreener
Kala Bio settles $10.6 million debt with Oxford Finance By Investing.com - Investing.com Nigeria
Kala Bio Settles Approximately $10.6 Million Of Debt - TradingView — Track All Markets
Kala Bio settles $10.6 million debt with Oxford Finance - Investing.com
Kala Bio fully settles loan, strengthens balance sheet - MSN
Kala Bio Inc pays $2 million to Oxford Finance LLC as part of settlement agreement - marketscreener.com
KALA BIO Announces Conditional Resignations of Six Directors - TradingView — Track All Markets
KALA BIO Directors Plan Conditional Resignations Tied to Vote - TipRanks
Top Penny Stocks To ResearchDecember 4th - MarketBeat
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Support Test: What insider trading reveals about AAOI stockJuly 2025 Sentiment & High Return Trade Guides - moha.gov.vn
Market Review: How KALA BIO Inc. stock trades before earnings2025 Winners & Losers & Short-Term Swing Trade Alerts - Улправда
Will KALA BIO Inc. stock see PE expansion2025 Growth vs Value & High Win Rate Trade Tips - Улправда
How KALA BIO Inc. stock reacts to bond yieldsJuly 2025 Big Picture & Precise Buy Zone Identification - DonanımHaber
Can KALA BIO Inc. stock deliver sustainable ROEMarket Weekly Review & Growth Focused Stock Reports - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Check: Will KALA BIO Inc. stock see PE expansionRisk Management & Fast Exit and Entry Trade Guides - Улправда
How KALA BIO Inc. stock trades before earningsWeekly Market Report & Consistent Income Trade Recommendations - ulpravda.ru
Kala Bio Stock Slides 42% With A 8-Day Losing Spree - Trefis
KALA BIO Announces New CEO and Funding Deal - The Globe and Mail
Oxford Finance Llc Net Worth (2025) - GuruFocus
Kala Bio dismisses Deloitte as auditor, no successor named By Investing.com - Investing.com Canada
KALA BIO announces new CEO and funding deal - MSN
Kala Bio dismisses Deloitte as auditor, no successor named - Investing.com
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
Kala Bio sets annual meeting for January 30, 2026 and updates on investment agreements By Investing.com - Investing.com Nigeria
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
Can Sobha Limited Maintain Its Share of Global Market for Its ProductUtilities Sector Analysis & Affordable Portfolio Trading - earlytimes.in
Why Did KALA BIO Shares Jump Over 22% After Hours? - Sahm
What drives KALA BIO Inc stock priceSmall Cap Stock Opportunities & Low Risk Wealth Plans - earlytimes.in
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
2.13%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):